Goldman Sachs Maintains Buy on Veracyte, Lowers Price Target to $32
Portfolio Pulse from Benzinga Newsdesk
Goldman Sachs analyst Matthew Sykes has maintained a 'Buy' rating on Veracyte (NASDAQ:VCYT) but lowered the price target from $37 to $32.
October 23, 2023 | 1:07 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Goldman Sachs has maintained a 'Buy' rating on Veracyte but lowered the price target from $37 to $32.
The news is directly related to Veracyte and is likely to influence investor sentiment. While the 'Buy' rating is maintained, the lowering of the price target may indicate a potential decrease in the short-term upside potential of the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100